CIK 0001425205 · Accelerated filer
IOVANCE BIOTHERAPEUTICS, INC.
Sign in to watch- Ticker
- IOVA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753254381
- Phone
- 6502607120
- Business address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-11 | Vogt Frederick G Interim CEO & General Counsel | Option exercise | +200,000 | $7.55 | $1.5M | 795,447 |
| 2026-11-11 | Vogt Frederick G Interim CEO & General Counsel | Shares withheld for taxes | −191,303 | $8.09 | $1.5M | 604,144 |
| 2026-11-11 | Vogt Frederick G Interim CEO & General Counsel | Option exercise · Stock Option (right to buy) | −200,000 | 0 | ||
| 2026-11-10 | Kirby Daniel Gordon Chief Commercial Officer | Option exercise | +10,000 | 164,511 | ||
| 2026-11-10 | Kirby Daniel Gordon Chief Commercial Officer | Shares withheld for taxes | −3,935 | $8.08 | $32K | 160,576 |
| 2026-11-10 | Kirby Daniel Gordon Chief Commercial Officer | Option exercise · Restricted Stock Units | −10,000 | 50,003 | ||
| 2026-11-06 | Roche Corleen M. Chief Financial Officer | Option exercise | +12,500 | 41,257 | ||
| 2026-11-06 | Roche Corleen M. Chief Financial Officer | Shares withheld for taxes | −5,311 | $8.04 | $43K | 35,946 |
| 2026-11-06 | Roche Corleen M. Chief Financial Officer | Option exercise · Restricted Stock Units | −12,500 | 87,505 | ||
| 2026-09-30 | Berkowitz Noah Chief Medical Officer | Grant or award · Stock Options (Right to Buy) | +135,000 | 135,000 | ||
| 2026-09-30 | Berkowitz Noah Chief Medical Officer | Grant or award · Restricted Stock Units | +180,000 | 180,000 | ||
| 2026-09-30 | Berkowitz Noah Chief Medical Officer | Grant or award · Performance Stock Units | +135,000 | 135,000 | ||
| 2026-09-08 | Vogt Frederick G Interim CEO & General Counsel | Option exercise | +15,626 | 602,085 | ||
| 2026-09-08 | Vogt Frederick G Interim CEO & General Counsel | Shares withheld for taxes | −6,638 | $8.70 | $58K | 595,447 |
| 2026-09-08 | Vogt Frederick G Interim CEO & General Counsel | Option exercise · Restricted Stock Units | −15,626 | 93,756 | ||
| 2026-09-08 | BILINSKY IGOR Chief Operating Officer | Option exercise | +7,813 | 146,050 | ||
| 2026-09-08 | BILINSKY IGOR Chief Operating Officer | Shares withheld for taxes | −3,976 | $8.70 | $35K | 142,074 |
| 2026-09-08 | BILINSKY IGOR Chief Operating Officer | Option exercise · Restricted Stock Units | −7,813 | 46,878 | ||
| 2026-09-08 | Puri Raj K. Chief Regulatory Officer | Option exercise | +9,766 | 260,842 | ||
| 2026-09-08 | Puri Raj K. Chief Regulatory Officer | Shares withheld for taxes | −4,478 | $8.70 | $39K | 256,364 |
Page 1 of 14 · 280 trades